A practical path to autonomous manufacturing in pharma 

More complex therapies, pressure to accelerate production and fragmented legacy systems create difficult choices for life sciences manufacturers. Where can autonomy deliver value? What foundations need to come first? And how can teams introduce new capabilities within regulated operations? 

The Life Sciences Autonomous Factory offer with Siemens provides an answer to these questions. It connects manufacturing priorities with the operational changes and digital capabilities needed to move beyond isolated pilots toward increasingly autonomous factories. 

Whether you are modernizing an existing site or designing a new facility, you will need to build a roadmap that reflects your starting point and business priorities. 

What you’ll discover: 

  • How to assess your readiness. Evaluate maturity across manufacturing processes, factory technology and workforce capabilities to identify the gaps that matter most. 
  • Where to prioritize investment. Explore opportunities across drug substance production, solid-dose and injectable manufacturing, packaging and logistics. Assess use cases against business value, technical feasibility and compliance considerations. 
  • Which digital foundations support scale. Understand the role of trusted data, connected IT and operational technology, and architectures that link the shopfloor with edge and cloud capabilities. 
  • How to progress with appropriate oversight. Explore a phased approach from readiness assessment through pilot validation and wider deployment, with clear decision rights, workforce development and value tracking.